Literature DB >> 1659535

Granulocyte-macrophage colony stimulating factor does not improve neutrophil oxidative metabolism in a patient with variant X-linked chronic granulomatous disease.

T J Mühlebach1, H J Feickert, K Welte, R A Seger.   

Abstract

Variant X-linked chronic granulomatous disease (CGD) is characterised by a decreased but still measurable respiratory burst and cytochrome b content of phagocytes resulting in a clinically milder form of the disease. We examined the in vivo effect of recombinant human granulocyte-macrophage colony stimulating factor (rh-GM-CSF) on the neutrophil functions of a patient treated for liver abscess. The number of white blood cells was markedly increased at the highest dose of GM-CSF injected (30 micrograms/kg per day). This was mainly due to a large increase in eosinophils and to a lesser extent in neutrophils. No change in the deficient neutrophil respiratory burst nitroblue tetrazolium (NBT)-reduction, superoxide (O2-)-production and cytochrome b content was observed during 6 weeks of therapy with increasing doses of GM-CSF. No significant clinical improvement of the liver abscess was observed during treatment with GM-CSF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659535     DOI: 10.1007/bf02072210

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease.

Authors:  R A Ezekowitz; S H Orkin; P E Newburger
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

2.  Absence of both the 91kD and 22kD subunits of human neutrophil cytochrome b in two genetic forms of chronic granulomatous disease.

Authors:  C A Parkos; M C Dinauer; A J Jesaitis; S H Orkin; J T Curnutte
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

Review 3.  New perspectives in chronic granulomatous disease.

Authors:  R A Ezekowitz; P E Newburger
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

4.  Purification and partial characterization of the b-type cytochrome from human polymorphonuclear leukocytes.

Authors:  R Lutter; M L van Schaik; R van Zwieten; R Wever; D Roos; M N Hamers
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

5.  Stimulation of oxidative metabolism of granulocytes by recombinant granulocyte-macrophage-colony-stimulating-factor and a conditioned medium of a urinary bladder carcinoma cell line.

Authors:  M Klausmann; K H Pflüger; D Krumwieh; F R Seiler; K Havemann
Journal:  Blut       Date:  1987-05

6.  Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by the chemotactic peptide.

Authors:  S Kitagawa; A Yuo; L M Souza; M Saito; Y Miura; F Takaku
Journal:  Biochem Biophys Res Commun       Date:  1987-05-14       Impact factor: 3.575

7.  Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractants.

Authors:  R H Weisbart; L Kwan; D W Golde; J C Gasson
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

8.  Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator.

Authors:  R H Weisbart; D W Golde; S C Clark; G G Wong; J C Gasson
Journal:  Nature       Date:  1985 Mar 28-Apr 3       Impact factor: 49.962

9.  Cellular and molecular effects of recombinant interferon gamma in chronic granulomatous disease.

Authors:  P E Newburger; R A Ezekowitz
Journal:  Hematol Oncol Clin North Am       Date:  1988-06       Impact factor: 3.722

Review 10.  Chronic granulomatous disease, a heterogeneous syndrome.

Authors:  W H Hitzig; R A Seger
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

View more
  4 in total

1.  Xanthine oxidase contributes to host defense against Burkholderia cepacia in the p47(phox-/-) mouse model of chronic granulomatous disease.

Authors:  B H Segal; N Sakamoto; M Patel; K Maemura; A S Klein; S M Holland; G B Bulkley
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Phagocyte NADPH oxidase, but not inducible nitric oxide synthase, is essential for early control of Burkholderia cepacia and chromobacterium violaceum infection in mice.

Authors:  Brahm H Segal; Li Ding; Steven M Holland
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

Review 3.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817

Review 4.  Raising the 'Good' Oxidants for Immune Protection.

Authors:  Alexia Dumas; Ulla G Knaus
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.